Hyperforin plasma level as a marker of treatment adherence in the national institutes of health hypericum depression trial

Journal of Clinical Psychopharmacology

Volumn 25, Issue 3, 2005, Pages 243-249

  Vitiello, Benedetto ^a   Shader, Richard I ^b   Parker, Corette B ^c   Ritz, Louise ^a   Harlan, William ^a   Greenblatt, David J ^b   Gadde, Kishore M ^d   Krishnan, K Ranga R ^d   Davidson, Jonathan R T ^d  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c RTI INTERNATIONAL   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPERFORIN; HYPERICUM EXTRACT; PLACEBO; SERTRALINE;

ADULT; ANORGASMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG METABOLISM; EDEMA; FEMALE; HEALTH CARE ORGANIZATION; HUMAN; HYPERICUM PERFORATUM; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MICTURITION DISORDER; OUTPATIENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; BICYCLO COMPOUNDS; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERICUM; MALE; MIDDLE AGED; NATIONAL INSTITUTES OF HEALTH (U.S.); PATIENT COMPLIANCE; PHLOROGLUCINOL; STATISTICS, NONPARAMETRIC; TERPENES; UNITED STATES;

EID: 18844382176     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000162801.72002.85     Document Type: Article

References (13)

1. Friedman LM, Furberg CD, DeMets DL. Fundamentals of Clinical Trials. 3rd ed. New York, NY: Springer-Verlag; 1998.
2. George CF, Peveler RC, Heiliger S, et al. Compliance with tricyclic antidepressants: the value of four different methods of assessment. Br J Clin Pharmacol. 2000;50:166-171.
3. Akerblad A-C, Bengtsson F, Ekselius L, et al. Effects of an educational compliance enhancement programme and therapeutic drug monitoring on treatment adherence in depressed patients managed by general practitioners. Int Clin Psychopharmacol. 2003;18:347-354.
4. Hypericum Depression Trial Study Group An extract of Hypericum perforatum (St. John's Wort) in major depressive disorder: a randomized, double-blind trial with placebo and active control. JAMA. 2002;287:1807-1814.
5. Bech P, Cialdella P, Haugh MC, et al. Meta-analysis of randomized controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression. Br J Psychiatry. 2000;176:421-428.
6. Mocrieff J, Wessley S, Hardy R. Meta-analysis of trials comparing antidepressants with active placebo. Br J Psychiatry. 1998;172:227-231.
7. Laakman G, Schuele C, Baghai T, et al. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry. 1998;31(S1):54-59.
8. Cervo L, Rozio M, Ekalle-Soppo CB, et al. Role of hyperforin in the antidepressant-like activity of Hypericum perforatum extracts. Psychopharmacology. 2002;164:423-428.
9. Nahrestedt A, Butterweck V. Biologically active and other chemical constituents of the herb Hypericum perforatum. Pharmacopsychiatry. 1997;30:S2:129-134.
10. Cui Y, Gurley B, Ang CYW, et al. Determination of hyperforin in human plasma using solid-phase extraction and high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;780:129-135.
11. Biber A, Fischer H, Roemer A, et al. Oral bioavailability of hyperforin extracts in rats and human volunteers. Pharmacopsychiatry. 1998;31(S1):36-43.
12. Bauer S, Stormer E, Graubaum HJ, et al. Determination of hyperforin, hypericin, and pseudohypericin in human plasma using high-performance liquid chromatography analysis with fluorescence and ultraviolet detection. J Chromatogr Biomed Sci Appl. 2001;765:29-35.
13. DeVane CL, Liston HL, Markowitz JS. Clinical pharmacokinetics of sertraline. Clin Pharmacokinet. 2002;41:1247-1266.